In ER+ breast cancers, nuclear p21-activated kinase 4 (nPAK4) targets LIFR, augmenting the PAK4-ER axis-mediated bone metastases, and functions as a novel repressor of ERα-mediated transactivation, operating in an E2-dependent manner (117). Here, ESR1 is linked to breast cancer.